WHO ICTRP trial
A single-center, open-label, randomized controlled phase 3 clinical study of…
ChiCTR2400080591 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2400080591 |
|---|---|
| Public title | A single-center, open-label, randomized controlled phase 3 clinical study of neoadjuvant chemotherapy combined with immunotherapy for cervical lymph node dissection in upper thoracic esophageal squamous cell carcinoma |
| Scientific title | A single-center, open-label, randomized controlled phase 3 clinical study of neoadjuvant chemotherapy combined with immunotherapy for cervical lymph node dissection in upper thoracic esophageal squamous cell carcinoma |
| Primary sponsor | The First Affiliated Hospital of Zhengzhou University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 3 |
| Countries | China |
| Conditions | Esophageal carcinoma |
| Interventions | Group A: Two field lymph node dissection:camrelizumab: 200 mg IVGTT D1 once every 3 weeks; 21-day cycles; nab-paclitaxel: 260 mg/m2 ivgtt D1 for 1 cycle in 21 days; Cisplatin: 75mg/m2, d1; Administered by intravenous infusion for 1 cycle… |
| Registration date | Feb 1, 2024 |
| Target size | Group A: Two field lymph node dissection:210;Group B: Three field lymph node… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: